Deborah Stewart Sells 10,896 Shares of Aveanna Healthcare (NASDAQ:AVAH) Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) CAO Deborah Stewart sold 10,896 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $7.38, for a total transaction of $80,412.48. Following the sale, the chief accounting officer directly owned 312,988 shares in the company, valued at $2,309,851.44. This trade represents a 3.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Deborah Stewart also recently made the following trade(s):

• On Thursday, February 19th, Deborah Stewart sold 11,181 shares of Aveanna Healthcare stock. The shares were sold at an average price of $7.21, for a total value of $80,615.01.
• On Tuesday, February 17th, Deborah Stewart sold 7,738 shares of Aveanna Healthcare stock. The shares were sold at an average price of $7.65, for a total value of $59,195.70.
• On Friday, January 2nd, Deborah Stewart sold 11,962 shares of Aveanna Healthcare stock. The stock was sold at an average price of $7.85, for a total value of $93,901.70.
• On Wednesday, December 31st, Deborah Stewart sold 11,275 shares of Aveanna Healthcare stock. The shares were sold at an average price of $8.18, for a total value of $92,229.50.
• On Tuesday, December 30th, Deborah Stewart sold 11,379 shares of Aveanna Healthcare stock. The stock was sold at an average price of $8.36, for a total value of $95,128.44.

Aveanna Healthcare Stock Performance

NASDAQ:AVAH opened at $7.34 on Friday. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 140.39. Aveanna Healthcare Holdings Inc. has a twelve month low of $3.67 and a twelve month high of $10.32. The company has a fifty day moving average of $8.45 and a 200-day moving average of $8.46. The firm has a market capitalization of $1.53 billion, a P/E ratio of 20.39 and a beta of 2.06.

Institutional Investors Weigh In On Aveanna Healthcare

Institutional investors have recently bought and sold shares of the stock. Quantbot Technologies LP purchased a new stake in Aveanna Healthcare in the 2nd quarter valued at $43,000. Lion Street Advisors LLC bought a new stake in shares of Aveanna Healthcare in the 3rd quarter worth $89,000. MQS Management LLC purchased a new stake in shares of Aveanna Healthcare in the second quarter valued at about $59,000. EverSource Wealth Advisors LLC lifted its position in shares of Aveanna Healthcare by 88,100.0% during the third quarter. EverSource Wealth Advisors LLC now owns 11,466 shares of the company’s stock valued at $102,000 after purchasing an additional 11,453 shares in the last quarter. Finally, Belvedere Trading LLC purchased a new position in Aveanna Healthcare during the second quarter worth about $62,000. Institutional investors own 87.96% of the company’s stock.

Trending Headlines about Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Institutional buying in recent quarters — firms including Invesco, Millennium, Zimmer Partners and others increased or established positions in Q4, a vote of confidence that can support the stock over the medium term. MarketBeat Institutional Activity
• Positive Sentiment: Despite recent sales, insiders still retain large, multi‑million‑dollar stakes (CEO, CFO and others remain major shareholders), which can temper panic selling and signal some continued alignment with shareholders. SEC Filing
• Neutral Sentiment: Reported short interest shows zero shares for mid‑February — this is almost certainly a reporting/data anomaly and does not indicate genuine lack of short interest. Treat the short‑interest figure cautiously. Short Interest Data
• Neutral Sentiment: Trading volume today was below recent averages; low volume can amplify price moves when large blocks or news hit the tape (higher intraday volatility risk).
• Neutral Sentiment: Analyst coverage remains mixed: consensus is around a “Hold” with an average target near $11 — helpful context for longer‑term positioning but not an immediate catalyst. Analyst Summary
• Negative Sentiment: Large, concentrated insider selling Feb. 17–19 by CEO Jeff Shaner — roughly 461,900 shares sold across three days (~$3.4M reported proceeds) — is the primary negative catalyst driving downward pressure as the market interprets sizeable CEO disposals as risk reduction. CEO Sales SEC Filing
• Negative Sentiment: Additional senior/executive selling (CFO Matthew Buckhalter, CAO Deborah Stewart, and other insiders including Edwin C. Reisz and Patrick A. Cunningham) involved hundreds of thousands of shares total across the same dates — a reinforcing negative signal that likely amplified the pullback. Other Insider Filings
• Negative Sentiment: Independent coverage singled out the insider selling as the main reason for a recent ~5–6% pullback, increasing market attention on the disposals and reinforcing short‑term selling pressure. AAII Article

Wall Street Analyst Weigh In

Several analysts have recently commented on AVAH shares. William Blair started coverage on Aveanna Healthcare in a research note on Monday, December 8th. They issued an “outperform” rating for the company. Jefferies Financial Group raised their price objective on Aveanna Healthcare from $11.00 to $12.50 and gave the company a “buy” rating in a research note on Tuesday, October 28th. Truist Financial upped their target price on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “hold” rating in a research report on Friday, November 7th. UBS Group increased their target price on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “neutral” rating in a report on Thursday, January 15th. Finally, Royal Bank Of Canada upped their price objective on shares of Aveanna Healthcare from $10.00 to $11.00 and gave the stock a “sector perform” rating in a report on Thursday, January 15th. Five investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $11.06.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.